UPDATE : Monday, October 14, 2019
상단여백
Kolon confident to resume US trial on Invossa
The government has decided to nullify Invossa-K’s license effective next Tu...
by Lee Hye-seon  |  2019-07-04 14:05
라인
China OKs Alteogen’s Herceptin biosimilar for clinical trials
Alteogen said that Qilu Pharmaceutical, its Chinese partner, has received i...
by Lee Han-soo  |  2019-07-04 14:04
라인
Regulator revokes Invossa license; Kolon CEO ‘to fight in court’
Kolon Life Science CEO said he would seek an administrative suit against th...
by Lee Hye-seon  |  2019-07-03 11:52
라인
BNO BIO to invest $1 million in Israeli biotech venture
BNO BIO, a joint venture between Bukwang Pharm and chemical and energy comp...
by Jeong Sae-im  |  2019-06-28 16:10
라인
Shareholders in shock over HLB’s phase-3 trial setback
Investors in HLB have expressed shock after the KOSDAQ-listed firm announce...
by Jeong Sae-im  |  2019-06-28 10:47
라인
‘Food and drug ministry alone can’t handle Invossa debacle’
“The National Medical Center (NMC), the Korea Centers for Disease Control a...
by Jeong Sae-im  |  2019-06-27 12:45
라인
Oscotech wins exception policy for continued R&D for new drugs
The stock market regulator granted Oscotech to become the third KOSDAQ-list...
by Jeong Sae-im  |  2019-06-25 14:11
라인
Despite regulator’s ruling delay, Kolon TissueGene likely to be reviewed for delisting
The stock market regulator said it has pushed back the deadline to decide w...
by Jeong Sae-im  |  2019-06-20 14:20
라인
294 shareholders file suit against Kolon TissueGene for damage compensation
Kolon TissueGene said in a public filing on Thursday that its 294 minority ...
by Jeong Sae-im  |  2019-06-14 10:51
라인
Celltrion unveils P3 trial results for rheumatoid biosimilar in Europe
Celltrion has presented the phase 3 clinical trial result for Remsima SC, t...
by Lee Han-soo  |  2019-06-13 16:10
라인
Kolon TissueGene CEO resigns
Kolon TissueGene, a subsidiary of Kolon Life Science, said Co-CEO Lee Woo-s...
by Jeong Sae-im  |  2019-06-07 15:35
라인
[ASCO 2019] ‘Ontruzant demonstrates equal quality to original drug’
CHICAGO, Ill. -- Samsung Bioepis has proved its quality control ability, as...
by Lee Han-soo, KBR correspondent  |  2019-06-04 14:17
라인
Kolon’s minority shareholders demand over ₩25 billion in damage
Minority shareholders of Kolon Life Science and its subsidiary Kolon Tissue...
by Jeong Sae-im  |  2019-06-03 14:53
라인
Invossa inventor sold Kolon shares at highest value
Former Kolon TissueGene CEO Lee Kwan-hee, the inventor of now-suspended gen...
by Jeong Sae-im  |  2019-06-03 14:52
라인
Until when will Kolon keep lying about Invossa?
Kolon Life Science’s “explanations” about the mislabeling of the cell ingre...
by Jeong Sae-im  |  2019-05-31 14:59
라인
Samsung BioLogics agrees to manufacture CytoDyn’s HIV drug
Samsung BioLogics said it has signed a deal with U.S. biotech firm CytoDyn ...
by Jeong Sae-im  |  2019-05-31 14:59
라인
Announcement of Invossa license revocation was ‘procedural breach’: Kolon
The government’s recent announcement that it would nullify the license of I...
by Jeong Sae-im  |  2019-05-30 13:28
라인
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy
Oncology researchers around the world are paying keen attention to MDM2 (mo...
by Kim Yun-mi  |  2019-05-29 12:35
라인
Invossa poses almost no safety threat: regulator
The Ministry of Food and Drug Safety said there was no significant concern ...
by Lee Hye-seon  |  2019-05-28 16:02
라인
Brazil OKs Samsung Bioepis’ trastuzumab biosimilar
Brazil’s Agencia Nacional de Vigilancia Sanitaria has granted marketing aut...
by Lee Han-soo  |  2019-05-27 15:52
여백
여백
여백
Back to Top